Equities analysts expect Teligent Inc (NASDAQ:TLGT) to announce $19.82 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Teligent’s earnings, with the highest sales estimate coming in at $20.20 million and the lowest estimate coming in at $19.44 million. Teligent posted sales of $18.29 million during the same quarter last year, which suggests a positive year over year growth rate of 8.4%. The business is expected to announce its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Teligent will report full year sales of $73.07 million for the current financial year, with estimates ranging from $72.53 million to $73.60 million. For the next fiscal year, analysts expect that the business will post sales of $89.45 million, with estimates ranging from $88.70 million to $90.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Teligent.
Teligent (NASDAQ:TLGT) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $18.34 million during the quarter, compared to analyst estimates of $17.58 million. Teligent had a negative net margin of 46.67% and a negative return on equity of 102.17%.
Several institutional investors have recently modified their holdings of TLGT. Jane Street Group LLC bought a new stake in Teligent during the second quarter valued at approximately $46,000. TENOR CAPITAL MANAGEMENT Co. L.P. bought a new stake in Teligent during the second quarter valued at approximately $44,000. First Light Asset Management LLC lifted its position in Teligent by 113.3% during the second quarter. First Light Asset Management LLC now owns 3,227,003 shares of the company’s stock valued at $2,033,000 after purchasing an additional 1,713,824 shares during the last quarter. Morgan Stanley lifted its position in Teligent by 247.0% during the second quarter. Morgan Stanley now owns 72,655 shares of the company’s stock valued at $45,000 after purchasing an additional 51,718 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Teligent during the second quarter valued at approximately $120,000. 56.07% of the stock is owned by institutional investors and hedge funds.
Shares of Teligent stock traded down $0.01 during midday trading on Wednesday, reaching $0.69. The company had a trading volume of 259,055 shares, compared to its average volume of 212,449. The company has a current ratio of 1.61, a quick ratio of 0.86 and a debt-to-equity ratio of 23.23. The company has a market capitalization of $37.88 million, a price-to-earnings ratio of -2.09 and a beta of 1.59. The stock has a fifty day simple moving average of $0.68 and a 200 day simple moving average of $0.95. Teligent has a 1-year low of $0.42 and a 1-year high of $4.40.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Read More: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.